Inactivated vaccines articles from across Nature Portfolio

In this study, authors identified neutralizing antibodies by isolating B cells from SARS-CoV-2 Delta infected patients and detect altered structural features, likely introduced by somatic hypermutation, that are involved in epitope binding and increase neutralization breadth against virus variants.

Li et al. evaluate the immunogenicity and safety of the CoronaVac inactivated COVID-19 vaccine in elderly patients with underlying medical conditions in China. Most patients show comparable neutralizing antibody and SARS-CoV-2-specific T cell responses to healthy controls, and no serious adverse effects are seen.

Few countries have approved SARS-CoV-2 booster doses in children and adolescents due to insufficient evidence about the safety and interval vaccination. Here, the authors assess the safety and immunogenicity of a homologous booster dose of CoronaVac in a cohort of 3–17 year olds.